TITLE

Disappointment at rimonabant halt

PUB. DATE
November 2008
SOURCE
Independent Nurse;11/3/2008, p4
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on clinicians' disappointment on the suspension of the weight-loss drug rimonabant, issued by the European Medicines Agency (EMEA). It is stated that EMEA raised concerns about the risk of psychiatric disorders in patients treated with the drug, and warned no further prescriptions for it should be issued. However, Sanofi-Aventis, manufacturer of rimonabant, said it was complying with EMEA's recommendation.
ACCESSION #
35184172

 

Related Articles

  • The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity Agents. Hyeon-Kyu Lee; Eun Bok Choi; Chwang Siek Pak // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p482 

    Since the discovery of rimonabant (Acomplia: 1), a large effort has been directed at the discovery of new, potent and selective CB1R antagonists that serve as anti obesity drugs. As a result, a number of compounds reached various stages of clinical trials by late 2008. However, the announcement...

  • WEIGHT LOSS MEDICATION INCREASES DEPRESSION RISK.  // RN;Dec2007, Vol. 70 Issue 12, p30 

    The article focuses on a meta-analyis of rimonabant which revealed that the weight-loss drug increases the risk of depression and anxiety and can increase users' suicidal thoughts. The drug targets the endocannabinoid system of the brain, which helps trigger and reward food intake....

  • Obesity drug no longer recommended.  // Practice Nurse;11/7/2008, Vol. 36 Issue 8, p8 

    The article announces the withdrawal of the obesity drug rimonabant by Sanofi-Aventis, following a decision by the European Medicines Agency (EMEA) to suspend its marketing authorisation. Rimonabant was first authorised for use in Europe in 2006 to help overweight and obese people lose weight,...

  • Suicide fears over weight-loss drug.  // PRWeek (London);7/4/2008, p6 

    The article looks at the suicide concerns over the weight-loss drug Acomplia, manufactured by Sanofi-Aventis. The drug has been approved by the British National Institute for Health and Clinical Excellence (NICE) and it is licensed in the Great Britain for the treatment of obese and overweight...

  • Withdrawal of Rimonabant - Walking the Tightrope of 21st Century Pharmaceutical Regulation? Taylor, David // Current Drug Safety;Jan2009, Vol. 4 Issue 1, p2 

    The author examines whether the proposal of the European Medicines Agency (EMEA) to temporary suspend the marketing authorisation for rimonabant (Acomplia), due to fears over the drug's association with psychiatric adverse events, is reasonable. He discusses the benefits and risks of the drug....

  • CHMP recommends against Qsiva approval.  // Reactions Weekly;11/3/2012, Issue 1426, p4 

    The article reports on the recommendation made by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for the refusal of marketing authorisation for the fixed combination anti-obesity drug Qsiva, saying that the drug's benefits do not outweigh its risks.

  • EMEA recommends suspending Acomplia.  // Reactions Weekly;11/1/2008, Issue 1226, p3 

    This article reports that the European Medicines Agency (EMEA) recommended suspending the marketing authorisation for the weight-loss drug Acomplia from Sanofi-Aventis after the Committee for Medicinal Products for Human Use (CHMP) concluded that its benefits no longer outweigh its risks....

  • Panel advises against rimonabant approval. Traynor, Kate // American Journal of Health-System Pharmacy;7/15/2007, Vol. 64 Issue 14, p1460 

    The article reports on the warning given by the members of the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration against rimonabant, a weight-management drug from Sanofi Aventis SA. Committee member Jules Hirsch stated that he would not suggest...

  • China Bans Weight-Loss Drug Fenfluramine Hydrochloride.  // China Chemical Reporter;1/26/2009, Vol. 20 Issue 3, p6 

    The article reports that China's State Food and Drug Administration (SFDA) ordered a nationwide ban on the production, sale and uses of fenfluramine hydrochloride, a kind of fat loss drug in the forms of ingredients and preparations on January 8, 2009. It is reported the diet drug can cause...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics